Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 69

Results For "PLI"

3553 News Found

FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia
News | September 30, 2025

FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia

FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses


AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
News | September 29, 2025

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs


DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
Biotech | September 29, 2025

DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland

The new site enables end-to-end production of viral vector gene therapies


Fujifilm Biotechnologies opens cell culture manufacturing site in North Carolina
Biotech | September 26, 2025

Fujifilm Biotechnologies opens cell culture manufacturing site in North Carolina

Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031


Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr
News | September 26, 2025

Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr

BIL also holds an option to increase its equity stake by an additional 15%


FDA approves Alembic’s Paroxetine ER tablets
Drug Approval | September 26, 2025

FDA approves Alembic’s Paroxetine ER tablets

Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder


DMMA warns regulatory burden threatening Gujarat’s pharma MSMEs
Policy | September 26, 2025

DMMA warns regulatory burden threatening Gujarat’s pharma MSMEs

The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.